TY  - JOUR
TT  - TARGETING CYCLOOXYGENASE-2 WITH A TARGETED LIPOSOMAL FORMULATION FOR COLORECTAL CANCER.
AU  - Banerjee, Sreeparna
PY  - 2017
DA  - February
JF  - The Turkish Journal Of Occupational / Environmental Medicine and Safety
JO  - turjoem
PB  - Engin TUTKUN
WT  - DergiPark
SN  - 2149-4711
SP  - 88
EP  - 88
VL  - Volume 2
IS  - İssue 1 (1)
KW  - TARGETING CYCLOOXYGENASE-2 WITH A TARGETED LIPOSOMAL FORMULATION FOR COLORECTAL CANCER.
N2  - Cyclooxygenase-2(COX-2) is highly expressed in many different cancers; particularly incolorectal cancer (CRC). Liposomal drug delivery systems can be used toincrease the therapeutic efficacy of CLX while minimizing its side effects.Cetuximab (anti-Epidermal Growth Factor Receptor -EGFR- monoclonal antibody) isa promising targeting ligand since EGFR is highly expressed in a wide range ofsolid tumors. Dual targeting of EGFR and COX-2 signaling may have additive orsynergistic effects. Here, we describe an EGFR-targeted immunoliposome forenhancing the delivery of CLX to cancer cells. Cell association studies indicated that the immunoliposome uptake washigher in EGFR-overexpressing cells compared to the non-targeted liposomes. Inaddition, the CLX-loaded-anti-EGFR immunoliposomes were significantly moretoxic compared to the non-targeted ones in cancer cells with EGFR-overexpressionbut not in the cells with low EGFR expression, regardless of their COX-2expression status. Thus, selective targeting of CLX with anti-EGFRimmunoliposomes appears to be a promising strategy for therapy of tumors thatoverexpress EGFR.   BAP-07-02-2014-004 and TÜBA-GEBİP
CR  - Sreeparna BANERJEE
Department of Biological Sciences, Middle East Technical University, Ankara, Turkey
UR  - https://dergipark.org.tr/tr/pub/turjoem/issue//305542
L1  - https://dergipark.org.tr/tr/download/article-file/293089
ER  -